Randomized clinical trial comparing two natural surfactant preparations to treat respiratory distress syndrome

References

• Palta M, Weinstein MR, McGuinness G, et al. A population study. Mortality and morbidity after availability of surfactant therapy. Newborn Lung Project. Arch Pediatr Adolesc Med 1994;148:1295–301
   Google Scholar
• Schwartz RM, Luby AM, Scanlon JW, et al. Effectofsurfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g. NEngIJMed 1994;330:1476–80
   PubMed Web of Science ®Google Scholar
• Ferrara TB, Hoekstra RE, Couser RJ, et al. Survival and follow-up of infants born at 23 to 26 weeks gestational age: effects of surfactant therapy. JPediatr 1994;124:119–24
   PubMed Web of Science ®Google Scholar
• Corbet A, Bucciarelli R, Goldman S, etal. Decreased mortality among small premature infants treated at birth with a single dose of synthetic surfactant: a multicentre controlled trial. JPediatr 1991;119:455–7
   PubMedGoogle Scholar
• Davis AJ, Jobe AH, Hafner D, et al. Lung function in premature lambs and rabbits treated with a recombinant SP-C surfactant. Am J Respir Crit Care Med 1998;157:553–9
   PubMed Web of Science ®Google Scholar
• Hall SB, Venkitaraman AR, Whitsett JA, etal. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants. Am Rev Respir Dis 1992;145:24–30
   PubMed Web of Science ®Google Scholar
• Sandberg KL, Lindstrom DP, Sjöqvist BA, et al. Surfactant replacement therapy improves ventilation in homogeneity in infants with respiratory distress syndrome. Pediatr Pulmonol 1997;24:337–43
   Google Scholar
• Jobe AH. Pulmonary surfactant therapy [review].N EnglJ Med 1993;328:861–8
   PubMed Web of Science ®Google Scholar
• Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2000;CD001079
   Google Scholar
• Bose C, Corbet A, Bose G, etal. Improved outcome at 28 days of age for very low birthweight infants treated with a single dose of synthetic surfactant. JPediatr 1990;117:947–53
   PubMed Web of Science ®Google Scholar
• Lemons JA, Bauer CR, Oh W, et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1995 through December 1996. Pediatrics 2001;107:E1
   PubMed Web of Science ®Google Scholar
• Hudak ML, Martin DJ, Egan EA, et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neo-natal respiratory distress syndrome. Pediatrics 1997;100:39–50
   PubMed Web of Science ®Google Scholar
• Soll RF. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2001 ; (2)CD000144
   Google Scholar
• Speer CP, Gefeller O, GroneckP, etal. Randomized clinical trial of two treatment regimens of natural surfactant prepara-tion in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonat Educ 1995;72:F8–13
   PubMed Web of Science ®Google Scholar
• Bloom BT, KattwinkelJ,Hall RT, et al. Comparisonofinfasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics 1997;100:31–8
   PubMed Web of Science ®Google Scholar
• Clark, Auten RL, Peabody J. A comparison of the outcomes of neonates treated with two different natural surfactants. JPediatr 2001;139:828–31
   Google Scholar
• Papile LA, Burstein J, Burstein R, et al. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gams. JPediatr 1978;92:529–34
   PubMed Web of Science ®Google Scholar
• Bell MJ, Ternberg JL, Feigin RD, etal. Neonatal necrotizing enterocolitis: therapeutic decisions based upon clinical staging. Ann Surg 1978;187:1–7
   PubMed Web of Science ®Google Scholar
• Sahai H, Kurshid A. Formula and tables for the determination of sample sizes and power in clinical trials for testing differ-ences in proportions for the two-sample design: a review. Stat Med 1996;15:1–21
   PubMed Web of Science ®Google Scholar
• Yu S, Harding GR, Smith M, et al. Bovine pulmonary surfactant: chemical composition and physical properties. Lipids 1983;18:522–9
   PubMed Web of Science ®Google Scholar
• Griese M, Dietrich P. Reinhardt D. Pharmacokinetics of bovine surfactant in neonatal respiratory distress syndrome. Am J Respir Crit Care Med 1995;152:1050–4
   PubMedGoogle Scholar
• Mizuno K, Ikegami M, Chen CM, etal. Surfactant protein-B supplementation improves in vivo function of a modified natural surfactant. Pediatr Res 1995;37:271–6
   PubMed Web of Science ®Google Scholar
• Bunt JE. Treatment with exogenous surfactant stimulates endogenous surfactant synthesis in premature infants with respiratory distress syndrome. Crit Care Med 2000;28:3383–8
   PubMed Web of Science ®Google Scholar
• Seeger W, Grube C, Gunther A, et al. Surfactant inhibition by plasma proteins: differential sensitivity of various sur-factant preparations. Eur Respir J1993;6:971–7
   PubMed Web of Science ®Google Scholar
• Holm BA. Surfactant replacement therapy, new levels of understanding. Am Rev Respir Dis 1993;148:834–6
   PubMedGoogle Scholar
• Hoekstra RE, Jackson JC, Myers TF, etal. Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at riskfor respiratory distress syndrome. Pediatrics 1991;88:10–18
   PubMed Web of Science ®Google Scholar
• Sibai BM. Hypertension in pregnancy. In Gabbe SG, Niebyl JR, Simpson JL, eds. Obstetrics: Normal &Problem Pregnancies, 3rd edn. New York: Churchill Livingstone 1996:935–97
   Google Scholar
• Page EW, Christianson R. Influence of blood pressure changes with and without proteinuria upon outcome of pregnancy. Am J Obstet Gynecol 1976;126:821–33
   PubMed Web of Science ®Google Scholar
• Van Marter LJ, Allied EN, Leviton A, et al. Antenatal glucocorticoid treatment does not reduce chronic lung disease among surviving preterm infants. J Pediatr 2001;138:198–204
   PubMed Web of Science ®Google Scholar
• Marshall DD, Kotelchuck M, Young TE, etal. Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. Pediatrics 1999;104:1345–50
   PubMed Web of Science ®Google Scholar
• Gunkel JH, Mitchell BR. Observational evidence for the efficacy of antenatal steroids from randomized studies of surfactantreplacement.AmJ Obstet Gynecoll 995;173:281–5
   Google Scholar
• Massaro GD, Massaro D. Formation of pulmonary alveoli and gas exchange surface area: quantitation and regulation. Ann Rev Physiol 1996;58:73–92
   PubMed Web of Science ®Google Scholar
• Jobe A. The new BPD: an arrest of lung development. Pediatr Res 1999;46:641–3
   PubMed Web of Science ®Google Scholar
• Bunt JE, Camielli VP, Darcos Wattimena JL, et al. The effect in premature infants of prenatal corticosteroids on endogenous surfactant synthesis as measured with stable isotopes. Am J Respir Crit Care Med 2000;162:844–9
   PubMed Web of Science ®Google Scholar
• Skov L, Bell A, Greisen G. Surfactant administration and the cerebral circulation. Biol Neonate 1992;61:31–6
   Google Scholar
• Rey M, Segerer H, Kiessling C, etal. Surfactant bolus instilla-tion: effects of different doses on blood pressure and cerebral blood flow velocities. Biol Neonate 1994;66:16–21
   PubMedGoogle Scholar
• Reller MD, Bufficin DC, Colasurdo MA, etal. Ductal patency in infants with respiratory distress syndrome. A randomized surfactant trial. Am J Dis Child 1991;145:1017–20
   PubMedGoogle Scholar